Danaher Corporation (DHR)
Health Care · Diversified life sciences, diagnostics, and industrial instrumentation · NYSE
Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally.
What Danaher Corporation does
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through a diversified portfolio of science and technology-based businesses, focusing on life sciences, diagnostics, and environmental and applied solutions. Its products are used extensively in research, laboratory, and production environments globally.
Themes: Clinical diagnostics, Life sciences research, Water quality and environmental monitoring, Product identification / track-and-trace, Dental/orthodontic equipment, Industrial instrumentation
Fundamentals
- Price$217.46 as of 2026-10-08 close
- Market cap$152.9B as of 2026-07-16 (share count; price 2026-10-08)
- 1-year return+6.1% 2025-10-08 close $204.96 → 2026-10-08 close $217.46
- P/E38.61 as of 2026-10-08
- Net margin+14.7% FY2025, SEC XBRL
- Gross margin+59.1% FY2025, SEC XBRL
- ROE+6.9% FY2025, SEC XBRL
- Debt / equity0.51 as of 2026-09-03
- Revenue growth (YoY)+4.6% as of 2026-09-03
- Revenue CAGR (3y)-2.7% SEC XBRL
- Beta0.78 as of 2026-09-03
- Last reported earnings2026-07-21 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.8%; pays a dividend.
How DHR compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DHR is not currently in any published Top 10 list. Its scores are below.
Top 10 score
52.3 #605 of 1,379 scored · #71 of 151 in Health Care
Capital return 78th (net share count bought back over the year 2.9) and financial health 67th (free cash flow margin 21.4%, debt to equity 0.5); weakest is growth (21st, 3-year revenue CAGR -2.7%, revenue growth year over year 4.6%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, DHR's dividend was covered by reported results (earnings payout 24%, free-cash-flow payout 17%). This describes past coverage, not a forecast.
- Earnings payout24% dividends / net income
- Free-cash-flow payout17% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Danaher Corporation looks technically
Danaher Corporation (DHR) is trading 7.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 17 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 7.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $210.58 | $210.58 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $202.08 | $202.08 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 211.18. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 17 trading days ago — a "golden cross", a bullish long-term signal | 17 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.6% above | +7.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 52.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($209.60 to $228.38) — its "stochastic" reading is 42 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 41.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $242.75 | $242.75 |
|---|---|---|
| From the 52-week high | it is 10.4% below its 52-week high (its highest price of the past year) | -10.4% |
| Above the 52-week low | it is 35.1% above its 52-week low (its lowest price of the past year) | +35.1% |
| Below the 52-week high | it is 10.4% below its highest point of the past year | 10.4% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $296.06 (set on 2021-09-10) | $296.06 |
| Given back of the 52-week move | over the past year its closes ranged ($161.91 to $242.05), and it has recovered well over two thirds of its fall from last year’s high — 69% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $211.44 to $214.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 69.3% |
| From the all-time high | it is 26.5% below its all-time high | -26.6% |
| Nearest price level | it is trading 1.6% above a support level at $214.07 — a price it turned at five times since 2025-02-21, most recently on 2026-10-01. Since 2024-10-08 it has 7 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.6% |
| All-time low | its lowest closing price on record is $3.28 (set on 1997-04-02) | $3.28 |
| Above the all-time low | it is 6538.9% above its all-time low | +6,539% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.58 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.58 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $201.78 and $230.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $201.78 – $216.29 – $230.80 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges above its 200-day average price (7.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.32× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.0% since the prior reading | +3.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.5% |
|---|---|---|
| Open gap | it gapped 3.3% above the previous close 54 sessions ago and has not traded back through the level it left behind at 179.14 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.3% |
| Gap filled | a 2.2% gap up opened on 2026-07-28 has been "filled" 50 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 50 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.9 percentage points (the stock gained 6.0% while the market gained 1.0%) | +4.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.2 percentage points (the stock gained 14.0% while the market gained 3.8%) | +10.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 4.3 percentage points (the stock gained 13.2% while the market gained 17.5%) | -4.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 8.9 percentage points (the stock gained 6.1% while the market gained 15.0%) | -8.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.7% of the share price. | +3.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $198.96 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +9.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-07-21 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $204.57 — a volume-weighted average of daily closes over 57 sessions, not a true tick-by-tick VWAP. | +6.3% |
Rising wedge, bearish — forming · entry $213.71 · 59 sessions in
Price levels it has turned at before
DHR last closed at $217.46 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $214.07 | Support | 1.6% below the last close | turned there five times · 2025-02-21 to 2026-10-01 |
| $221.06 | Resistance | 1.7% above the last close | turned there three times · 2025-10-03 to 2026-08-20 |
| $207.44 | Support | 4.6% below the last close | turned there 9 times · 2025-04-23 to 2026-08-10 |
| $227.48 | Resistance | 4.6% above the last close | turned there six times · 2024-11-18 to 2026-09-28 |
| $233.05 | Resistance | 7.2% above the last close | turned there four times · 2025-01-14 to 2025-12-12 |
| $200.23 | Support | 7.9% below the last close | turned there 10 times · 2025-02-12 to 2026-09-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $211.18.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $240.47 and $258.57 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $211.18.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 22 analysts
- Mean price target$239.50 range $200.00 – $310.00; median $240.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DHR
- Consensus EPS estimate$1.92 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.00102 (-0.1%) from $1.92, on 2026-09-03, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Foreign currency headwinds affecting reported results and competitive positioning in international markets","Acquired intangible assets of $21.4 billion and goodwill of $47.4 billion expose the company to impairment risk if acquisitions underperform","Rising interest expenses ($170 million in H1 2026) due to increased debt levels following acquisitions, impacting profitability"]
What changed in the latest 10-Q
AI-assisted comparison of DHR's 10-Q filed 2026-07-21 against the prior one filed 2026-04-21.
Management's Discussion & Analysis (MD&A)
- Reworded:
- In the newer filing dated 2026-07-21, the reference to the reporting period changed from "the three-month period ended March 27, 2026" to "the three and six-month periods ended June 26, 2026".
- In the newer filing dated 2026-07-21, Masimo is described as "our integration of Masimo and the anticipated benefits of such acquisition" whereas the older filing dated 2026-04-21 described it as "our pending acquisition of Masimo Corporation".
- In the newer filing dated 2026-07-21, the risk factor about the Middle East changed from "recent escalation of conflict in the Middle East" to "conflict in the Middle East".
- In the newer filing dated 2026-07-21, the risk factor about acquisitions changed from "our pending acquisition of Masimo Corporation" to "our recent acquisition of Masimo".
- Notes:
- The provided newer source text appears truncated in the Acquisitions, Divestitures and Investment Risks section, limiting comparison beyond that point to only the portion supplied.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 3 sells ($13M) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 4 sells ($13M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DHR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 24 matched disclosures for DHR from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding DHR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 118,220,452
- Reported value $22,529,894,562
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 6 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DHR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DHR had 8,344,032 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
DHR had 1.19% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.69 days to cover at the same settlement.
- Reported short interest (shares) 8,344,032
- Short interest (% of shares outstanding) 1.19%
- Prior settlement (shares) 9,639,180
- Reported change -13.44%
- Days to cover (reported) 2.69
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific
- Becton Dickinson (BDX)
- Abbott Diagnostics (ABT)
- Siemens Healthineers
- Roper Technologies (ROP)
- Xylem Inc. (XYL)
- PerkinElmer (PKI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DHR vs…
Danaher Corporation is found in…
Frequently asked questions
What does Danaher Corporation (DHR) do?
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through a diversified portfolio of science and technology-based businesses, focusing on life sciences, diagnostics, and environmental and applied solutions. Its products are used extensively in research, laboratory, and production environments globally.
What sector is Danaher Corporation (DHR) in?
Danaher Corporation (DHR) is classified in the Health Care sector. Its industry is Diversified life sciences, diagnostics, and industrial instrumentation. It trades on NYSE.
Does DHR pay a dividend?
Yes — Danaher Corporation (DHR) pays a dividend, with an indicated yield of about 0.76% (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Danaher Corporation's (DHR) competitors?
Notable peers of Danaher Corporation (DHR) include Thermo Fisher Scientific, Becton Dickinson, Abbott Diagnostics, Siemens Healthineers and Roper Technologies. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in DHR?
Yes — we hold 24 matched STOCK Act disclosures for DHR from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Danaher Corporation (DHR) overbought or oversold right now?
Danaher Corporation (DHR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DHR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.